San Diego, CA, USA, May 1, 2013 – The following data will be presented at the annual meeting of the American Urology Association (AUA) in San Diego, CA:
Date: Monday, May 6, 2013; 8:00-10:00 AM
Session/Type: Prostate Cancer: Advanced (II); Moderated Poster
Location: San Diego Convention Center, Room 7
Authors: Peter Albertsen; Bertrand Tombal; Thomas Wiegel; Egbert van der Meulen; Bo-Eric Persson; Tine Kold Olesen; Joshua Beckman
Date: Sunday, May 5, 2013; 3:30-5:30 PM
Session/Type: Prostate Cancer: Advanced (I); Podium Presentation
Location: San Diego Convention Center, Room 1
Authors: Neal Shore; Kurt Miller; Bertrand Tombal; E. David Crawford; Cathrina Karup; Egbert van der Meulen; Bo-Eric Persson
Per AUA media embargo policy, coverage of research being presented is prohibited before the date and time of presentation.
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries. To learn more about Ferring or its products, please visit http://www.ferring.com.
For More Information:
Tonic Life Communications
Tel: (215) 928-2357
Tel: +41 (0) 58 301 00 53
© 2013 Ferring B.V.
FIRMAGON® is a registered trademark of Ferring B.V.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.